Macquarie initiated coverage of Privia Health (PRVA) with an Outperform rating and $25 price target Privia is an enduring leader aiding the transformation of the trillion-dollar healthcare industry to value-based care, the analyst tells investors in a research note. Privia has built a lasting business model that will allow it to sustain its growth momentum in the many years ahead, the firm says.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA: